Phyllocontin® (aminophylline) Continus 225mg and Phyllocontin® Forte Continus 350mg modified-release tablets are being discontinued in the UK. Remaining supplies of the 225mg strength are expected to be exhausted by 2nd March 2021 and the 350mg strength are expected to be exhausted by 5th April 2021. All healthcare professionals in primary, secondary and specialist healthcare services who prescribe aminophylline preparations should not initiate new patients on aminophylline tablets (Phyllocontin® Continus 225mg and Forte Continus 350mg
Prescribers are asked to review all affected patients and optimise inhaled therapies. Patients who still require a methylxanthine, will need to
be switched to theophylline tablets (Uniphyllin Continus®). Details of dose conversions and monitoring requirements can be found in the alert.